Amneal Secures FDA Approval for Generic Albuterol Inhaler, Marking Second Respiratory Win in Q4 2025
核心洞察
Amneal Pharmaceuticals received FDA approval for its generic albuterol sulfate inhalation aerosol, equivalent to PROAIR HFA, targeting a $1.5 billion annual market.
This marks the company's second complex respiratory approval in Q4 2025, following beclomethasone dipropionate approval earlier in the quarter.
The generic albuterol inhaler is indicated for treating bronchospasm (搜索) in adults and children 12 years and older with reversible obstructive airway disease (搜索).
Amneal Pharmaceuticals has secured FDA approval for its generic albuterol sulfate inhalation aerosol (90 mcg per actuation), marking the company's second major respiratory therapeutic approval in the fourth quarter of 2025. The product serves as the generic equivalent of PROAIR HFA, manufactured by Teva Respiratory LLC (搜索), and targets a substantial market valued at approximately $1.5 billion in annual U.S. sales according to IQVIA data for the 12 months ended September 2025.
Strategic Respiratory Portfolio Expansion
This approval follows Amneal's earlier FDA clearance of beclomethasone dipropionate inhalation aerosol, a generic version of QVAR, demonstrating the company's accelerating momentum in complex inhaled drug delivery. The dual approvals underscore Amneal's strategic focus on building a differentiated, high-value respiratory portfolio supported by its advanced manufacturing capabilities.
"Securing two significant inhalation approvals this quarter—first beclomethasone dipropionate and now albuterol—highlights the tremendous progress our teams have made in a highly complex respiratory category," said Dr. Srinivas Kone, Senior Vice President, Chief Scientific Officer – Affordable Medicines. "These achievements are the result of years of hard work, engineering excellence, and investment in our respiratory platform, and they position Amneal to deliver meaningful growth and patient impact."
Clinical Profile and Market Access
The approved albuterol sulfate inhalation aerosol is indicated for the treatment or prevention of bronchospasm (搜索) in adults and children 12 years of age and older with reversible obstructive airway disease (搜索). Clinical data shows the most common adverse reactions occurring in ≥3.0% of patients and more frequently than placebo include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis.
Manufacturing Excellence in Complex Therapeutics
The approvals represent significant technical achievements in the challenging field of inhaled drug delivery, where precise engineering and manufacturing expertise are critical for regulatory success. Amneal's ability to secure two complex respiratory approvals within a single quarter demonstrates the maturation of its respiratory development platform and manufacturing capabilities.
The company's broader pharmaceutical portfolio encompasses over 290 products distributed primarily within the United States, with operations spanning affordable medicines, specialty pharmaceuticals focused on central nervous system and endocrine disorders, and federal government distribution through its AvKARE segment.